



AnorMED Inc.  
200 – 20353 64<sup>th</sup> Ave  
Langley, British Columbia  
Canada V2Y 1N5

TEL (604) 530-1057  
FAX (604) 530-0976  
www.anormed.com

## PRESS RELEASE

### **ANORMED INC. RAISES \$30.5 MILLION IN INITIAL PUBLIC OFFERING, SHARES LISTED FOR TRADING ON TORONTO STOCK EXCHANGE**

**For Immediate Release:**

**March 5, 1999**

**VANCOUVER, British Columbia** - AnorMED Inc. announced today that it has completed an Initial Public Offering of 5 million common shares at a price of \$6.10 per share for total gross proceeds of \$30.5 million, excluding an over allotment option granted to the underwriters. Concurrent with the completion of the offering, AnorMED common shares have been listed for trading on the Toronto Stock Exchange under the symbol "AOM".

"Completion of our Initial Public Offering is a major milestone for our Company. We now have the resources to aggressively push forward our drug discovery and development programs. Also, it is very encouraging to receive validation of our business plan and team from a demanding public equity market," said Dr. Michael Abrams, AnorMED's President and CEO.

"Our next Company milestone for 1999 will be the commencement of Phase II clinical trials for AMD-3100, our HIV treatment," Abrams said.

The Company's national underwriting syndicate was led by Nesbitt Burns Inc. and included CIBC Wood Gundy Securities Inc., RBC Dominion Securities Inc. and Goepel McDermid Inc.

AnorMED is a leader in the discovery of metal-based therapeutics. The company has five product candidates in clinical trials, including two in Phase III which is usually the final stage of testing before product approval can be applied for. Three other product candidates are in pre-clinical development.

AnorMED's business strategy is to add value to its product candidates by taking them into Phase II clinical trials, thereby establishing efficacy in human patients. The Company also seeks commercialization partnerships with pharmaceutical companies that are leaders in their respective fields to cover late-stage clinical trials, manufacturing and marketing. AnorMED has three such partnerships in place with Zeneca Limited of London, U.K., DuPont Pharmaceutical Company of Wilmington, Delaware, and Shire Pharmaceuticals Group PLC of East Anton, U.K.

These securities have not been and will not be registered under the United States Securities Act of 1933, as amended, and, subject to certain exemptions, may not be sold in the United States or to U.S. persons.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR  
DISSEMINATION IN THE UNITED STATES.

Note: Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

For further information:

Investor contact:  
Mr. W.J. (Bill) Adams, C.A.  
Chief Financial Officer  
Tel: (604) 530-1057  
e-mail: [info@anormed.com](mailto:info@anormed.com)

Media Contact:  
Karen Cook Boas or Kirstin McLellan  
James Hoggan and Associates  
Tel: (604) 739-7500  
e-mail: [kcook@hoggan.com](mailto:kcook@hoggan.com)